Ruxolitinib Tablets/Why Ruxolitinib is not included in the new special drug

Ruxolitinib tablets/Ruxolitinib, as a selective kinase inhibitor targeting JAK1 and JAK2, has been widely used worldwide to treat myelofibrosis (MF) and other related diseases. However, although it has achieved certain results in clinical application, there are still some factors that may cause it to fail to enter the new special drug catalog.

The selection criteria for the new special drug list usually include the efficacy, safety, innovation and clinical needs of the drug. Although ruxolitinib has shown certain efficacy in the treatment of myelofibrosis, it may not fully meet the inclusion criteria for the New Special Drug List in other aspects. For example, issues such as its long-term safety and drug resistance may require more in-depth research and evaluation.

The development and marketing of new specialty drugs requires a lengthy clinical trial and approval process, involving a large amount of capital investment and time costs. Although ruxolitinib has been marketed abroad and has gained certain clinical application experience, the research and development and approval process in the Chinese market may still be in progress, so it has not been included in the new special drug catalog for the time being.

In addition, the update and adjustment of the new special drug catalog is a dynamic process and requires timely adjustments based on clinical needs and drug research and development progress. As a new drug, ruxolitinib may need more clinical data and experience to support its status in the new special drug list.

Finally, it should be noted that although ruxolitinib has not been included in the new special drug catalog, this does not mean that it has no value or prospect in clinical application. In fact, ruxolitinib, as a selective kinase inhibitor targeting JAK1 and JAK2, provides new ideas and methods for the treatment of MF and other diseases.